IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
Naoyuki Nogami, Fabrice Barlési, Mark A. Socinski et al. · Journal of Thoracic Oncology · 2021
Cited by 302 works. doi:10.1016/j.jtho.2021.09.014
Authors
- Naoyuki Nogami
- Fabrice Barlési
- Mark A. Socinski
- Martin Reck
- Christian A. Thomas
- Federico Cappuzzo
- Tony S.K. Mok
- Gene Grant Finley
- Joachim G.J.V. Aerts
- Francesco Orlandi
- Denis Moro‐Sibilot
- Robert M. Jotte
- Daniil Stroyakovskiy
- Liza Cosca Villaruz
- Delvys Rodríguez‐Abreu
- Wan‐Teck Lim
- Shelley Coleman
- Geetha Shankar
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- The National Comprehensive Cancer Network
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses